E. Chen | AMiner学者主页

1Comparison of Performance of MET Amplification Detection by FISH, NGS and Ddpcr in EGFRm Advanced NSCLC Patients Post First-Line Osimertinib Treatment Failure: Analysis from a Prospective, Multi-Center Study in China

P. Xing,D. Lv, W. Feng, S. Liu,Y. Yu, J. Yin,X. Ren, J. Zhang, G. Han, Y. Zhang,S. Cang, J. Chen,

2024ANNALS OF ONCOLOGY

引用

AI阅读

2685P Genomic Profiles in EGFR Mutant Locally Advanced or Metastatic NSCLC Patients after First-Line Osimertinib Treatment Failure: A Real-World, Multi-Center Prospective Study in China

Y-k. Shi,D. Lv, W. Feng, S. Liu, P. Xing,Y. Yu, J. Yin,X. Ren, J. Zhang, G. Han, Y. Zhang,S. Cang,

2024ANNALS OF ONCOLOGY（2024）

引用

AI阅读

3519P Final Results and Subgroup Analysis of ORIENTAL: A Phase IIIB Study of Durvalumab Plus Platinum-Etoposide in First-Line Treatment of Chinese Patients with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Y. Cheng,J. Wang,W. Yao,Y. Yu,A. Zang,L. Cao,D. Lv, S. Li, Z. Meng, J. Zhang,Q. Guo,D. Huang,

The phase Ⅲ CASPIAN study established durvalumab (D) plus etoposide with cisplatin or carboplatin (EP) as first-line standard of care (1L SoC) of ES-SCLC. The multicenter, single-arm, phase Ⅲb ORIENTAL study evaluated 1L D+EP in a large, real-world-like patient (pt) cohort in China. Preliminary safety and efficacy results were consistent with CASPIAN. Here we report final results and subgroup analysis.

2023ANNALS OF ONCOLOGY（2023）引用：2

引用

AI阅读

4EP12.01-19 Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib

E. Chen,J. Lou, X. Hu,S. Wen, X. Zhu, Z. Jiang, Q. Li, L. Le, Y. Sheng, S. Wu, J. Zou, Y. Lu,

Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have revolutionized the standard treatment for EGFR sensitive and resistant mutated non-small cell lung cancer (NSCLC). Osimertinib as one of the third-generation EGFR-TKIs is currently the most advanced in clinical development worldwide. Interstitial lung disease (ILD) is a potentially fatal side effect of osimertinib use. The aim of this study was to evaluate the safety and efficacy of aumolertinib in EGFRm+ NSCLC patients with ILD after treatment with osimertinib.

2023JOURNAL OF THORACIC ONCOLOGY（2023）

引用

AI阅读

560Tip ORIENTAL: an Open Label, Multicenter, Phase IIIb Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Y. Cheng,J. Wang,S. Cang,L. Cao,E. Chen,X. Dong,Y. Fan,B. Gao,Q. Guo,D. Huang, S. Li,A. Liu,

2021JOURNAL OF THORACIC ONCOLOGY（2021）

引用

AI阅读

研究兴趣

作者统计

相似学者

研究兴趣

作者统计

相似学者